Rafferty Asset Management
PVLA

Rafferty Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Rafferty Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.82M Sell
14,590
-1,144
-7% -$119K 0.01% 629
2025
Q4 		$1.65M Buy
+15,734
New +$1.34M 0.01% 692
2022
Q3 		– Sell
-370
Closed -$55K – 1265
2022
Q2 		$55K Buy
370
+90
+32% +$16.4K ﹤0.01% 1097
2022
Q1 		$68K Buy
280
+23
+9% +$6.05K ﹤0.01% 1195
2021
Q4 		$78K Sell
257
-140
-35% -$44.8K ﹤0.01% 1269
2021
Q3 		$164K Buy
+397
New +$138K ﹤0.01% 1199

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Rafferty Asset Management's PVLA Position: Q1 2026 in Review

Rafferty Asset Management reduced its Palvella Therapeutics (PVLA) stake by 7.3% in Q1 2026, selling an estimated $119K and leaving 14,590 shares worth $1.82M. The position accounts for 0.01% of the portfolio, ranked #629.

Rafferty Asset Management first reported a position in PVLA in Q3 2021 and has held it in 6 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Rafferty Asset Management held 14,590 shares of Palvella Therapeutics worth $1.82M as of Q1 2026.
  • Rafferty Asset Management sold 1,144 Palvella Therapeutics shares in Q1 2026, an estimated $119K.
  • Palvella Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #629 holding.
  • Rafferty Asset Management first reported a position in Palvella Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.